1. Home
  2. NTLA vs OBK Comparison

NTLA vs OBK Comparison

Compare NTLA & OBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • OBK
  • Stock Information
  • Founded
  • NTLA 2014
  • OBK 1912
  • Country
  • NTLA United States
  • OBK United States
  • Employees
  • NTLA N/A
  • OBK N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • OBK Major Banks
  • Sector
  • NTLA Health Care
  • OBK Finance
  • Exchange
  • NTLA Nasdaq
  • OBK Nasdaq
  • Market Cap
  • NTLA 1.2B
  • OBK 1.1B
  • IPO Year
  • NTLA 2016
  • OBK 2018
  • Fundamental
  • Price
  • NTLA $10.90
  • OBK $37.37
  • Analyst Decision
  • NTLA Buy
  • OBK Buy
  • Analyst Count
  • NTLA 20
  • OBK 7
  • Target Price
  • NTLA $32.30
  • OBK $43.00
  • AVG Volume (30 Days)
  • NTLA 5.0M
  • OBK 159.2K
  • Earning Date
  • NTLA 08-07-2025
  • OBK 07-23-2025
  • Dividend Yield
  • NTLA N/A
  • OBK 1.61%
  • EPS Growth
  • NTLA N/A
  • OBK N/A
  • EPS
  • NTLA N/A
  • OBK 2.23
  • Revenue
  • NTLA $52,857,000.00
  • OBK $340,866,000.00
  • Revenue This Year
  • NTLA N/A
  • OBK $12.71
  • Revenue Next Year
  • NTLA N/A
  • OBK $7.32
  • P/E Ratio
  • NTLA N/A
  • OBK $16.70
  • Revenue Growth
  • NTLA 14.99
  • OBK N/A
  • 52 Week Low
  • NTLA $5.90
  • OBK $28.80
  • 52 Week High
  • NTLA $24.16
  • OBK $41.17
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 45.06
  • OBK 55.90
  • Support Level
  • NTLA $10.57
  • OBK $35.28
  • Resistance Level
  • NTLA $11.51
  • OBK $37.56
  • Average True Range (ATR)
  • NTLA 0.69
  • OBK 0.72
  • MACD
  • NTLA -0.26
  • OBK 0.02
  • Stochastic Oscillator
  • NTLA 10.44
  • OBK 64.46

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.

Share on Social Networks: